Sticking it to sickle cell

Global Blood Therapeutics Inc. raised $48 million in a series B round that will enable the company to reach clinical proof of concept for its lead sickle cell disease program in mid-2015, after which CEO Ted Love said the company hopes to go public.

Last week's round came from new investors Wellington Management Company, RA Capital, Deerfield Management, Sabby Capital, Perceptive Life Sciences, an affiliate of Cowen Group that was not named and an undisclosed "blue chip" public investment fund. ...